Wendy Johnson

Bio

Ms. Johnson joined ProQuest as a Venture Partner in 2005 and brings broad experience in licensing, strategy, and corporate development. She has successfully licensed multiple value-generating therapeutic products, negotiated acquisitions, and established several international strategic alliances. Prior to joining ProQuest, she served as Senior Vice President, Corporate Development, at Salmedix Inc., where she led the effort to license their lead cancer therapeutic; the company was successfully sold to Cephalon in June 2005. Ms. Johnson has additional experience with device, diagnostic and drug discovery and development and regulatory affairs. She held senior business and corporate development positions at Women First, Prizm Pharmaceuticals (currently Selective Genetics Inc.), Cytel Corp., Symbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the Food and Drug Administration. Currently, Ms. Johnson serves as the President and CEO of Aires Pharmaceuticals, a ProQuest portfolio company. M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland.